Apellis Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US03753U1060

Introduction

This page provides a comprehensive analysis of the known insider trading history of Pascal Deschatelets. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Pascal Deschatelets has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:APLS / Apellis Pharmaceuticals, Inc. Chief Scientific Officer 1,160,496
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Pascal Deschatelets. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases APLS / Apellis Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in APLS / Apellis Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

APLS / Apellis Pharmaceuticals, Inc. Insider Trades
Insider Sales APLS / Apellis Pharmaceuticals, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in APLS / Apellis Pharmaceuticals, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-01-29 APLS Deschatelets Pascal 826 29.5236 826 29.5236 24,386 106 16.3600 -10,873 -44.59
2025-01-22 APLS Deschatelets Pascal 3,948 30.4255 3,948 30.4255 120,120
2025-01-17 APLS Deschatelets Pascal 750 29.9582 750 29.9582 22,469
2025-01-13 APLS Deschatelets Pascal 2,288 28.7021 2,288 28.7021 65,670
2024-02-12 APLS Deschatelets Pascal 1,148 67.7669 1,148 67.7669 77,796
2024-01-29 APLS Deschatelets Pascal 874 64.1382 874 64.1382 56,057
2024-01-22 APLS Deschatelets Pascal 3,913 64.9960 3,913 64.9960 254,329
2024-01-16 APLS Deschatelets Pascal 1,632 66.8086 1,632 66.8086 109,032
2023-09-08 APLS Deschatelets Pascal 12,000 42.8700 12,000 42.8700 514,440
2021-03-10 APLS Deschatelets Pascal 6,250 50.7400 6,250 50.7400 317,125
2020-02-13 APLS Deschatelets Pascal 55,398 40.9790 55,398 40.9790 2,270,155
2020-02-12 APLS Deschatelets Pascal 52,075 42.8030 52,075 42.8030 2,228,966

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

APLS / Apellis Pharmaceuticals, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Pascal Deschatelets as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-05-22 2025-05-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 12,780 1,160,496 1.11 3.76 48,053 4,363,465
2025-01-30 2025-01-29 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -826 1,147,716 -0.07 29.52 -24,386 33,884,708
2025-01-23 2025-01-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -3,948 1,148,542 -0.34 30.43 -120,120 34,944,965
2025-01-21 2025-01-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 15,045 1,152,490 1.32
2025-01-21 2025-01-17 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -750 1,137,445 -0.07 29.96 -22,469 34,075,805
2025-01-14 2025-01-13 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -2,288 1,138,195 -0.20 28.70 -65,670 32,668,587
2024-05-21 2024-05-20 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 24,500 1,140,483 2.20 3.76 92,120 4,288,216
2024-05-09 2024-05-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -100 1,115,983 -0.01 44.02 -4,402 49,131,152
2024-05-09 2024-05-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -22,472 1,116,083 -1.97 42.85 -962,903 47,823,040
2024-05-09 2024-05-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -56,335 1,138,555 -4.71 42.15 -2,374,543 47,990,549
2024-05-09 2024-05-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 78,907 1,194,890 7.07 4.31 340,089 5,149,976
2024-04-09 2024-04-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -4,728 1,115,983 -0.42 54.92 -259,639 61,284,430
2024-04-09 2024-04-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -64,379 1,120,711 -5.43 54.12 -3,483,966 60,648,957
2024-04-09 2024-04-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 69,107 1,185,090 6.19 3.76 259,842 4,455,938
2024-03-11 2024-03-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -100 1,115,983 -0.01 63.35 -6,335 70,697,523
2024-03-11 2024-03-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -26,257 1,116,083 -2.30 62.69 -1,646,041 69,966,797
2024-03-11 2024-03-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -42,750 1,142,340 -3.61 61.88 -2,645,173 70,682,744
2024-03-11 2024-03-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 69,107 1,185,090 6.19 3.67 253,623 4,349,280
2024-02-13 2024-02-12 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -1,148 1,115,983 -0.10 67.77 -77,796 75,626,708
2024-01-31 2024-01-29 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -874 1,117,131 -0.08 64.14 -56,057 71,650,772
2024-01-23 2024-01-22 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -3,913 1,118,005 -0.35 65.00 -254,329 72,665,853
2024-01-17 2024-01-16 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -1,632 1,121,918 -0.15 66.81 -109,032 74,953,771
2024-01-17 2024-01-16 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 6,743 1,123,550 0.60
2023-11-15 2023-11-14 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 45,000 1,116,807 4.20 3.76 169,200 4,199,194
2023-11-09 2023-11-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 1,071,807 -1.11 47.27 -567,240 50,664,317
2023-11-09 2023-11-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 17,494 1,083,807 1.64 2.67 46,709 2,893,765
2023-10-10 2023-10-09 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 1,066,313 -1.11 40.38 -484,560 43,057,719
2023-10-10 2023-10-09 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18,500 1,078,313 1.75 2.67 49,395 2,879,096
2023-09-11 2023-09-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -12,000 1,059,813 -1.12 42.87 -514,440 45,434,183
2023-09-11 2023-09-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18,500 1,071,813 1.76 2.67 49,395 2,861,741
2023-08-09 2023-08-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 1,053,313 -1.13 23.66 -283,920 24,921,386
2023-08-09 2023-08-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18,500 1,065,313 1.77 2.67 49,395 2,844,386
2023-07-11 2023-07-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 1,046,813 -1.13 84.55 -1,014,600 88,508,039
2023-07-11 2023-07-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18,500 1,058,813 1.78 2.67 49,395 2,827,031
2023-06-09 2023-06-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 1,040,313 -1.14 91.35 -1,096,200 95,032,593
2023-06-09 2023-06-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18,500 1,052,313 1.79 2.67 49,395 2,809,676
2023-05-09 2023-05-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 1,033,813 -1.15 92.39 -1,108,680 95,513,983
2023-05-09 2023-05-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18,500 1,045,813 1.80 2.67 49,395 2,792,321
2023-04-11 2023-04-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 1,027,313 -1.15 78.21 -938,520 80,346,150
2023-04-11 2023-04-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18,500 1,039,313 1.81 2.67 49,395 2,774,966
2023-03-10 2023-03-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 1,020,813 -1.16 63.79 -765,480 65,117,661
2023-03-10 2023-03-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18,500 1,032,813 1.82 2.67 49,395 2,757,611
2023-02-22 2023-02-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -1,195 1,014,313 -0.12 58.50 -69,908 59,337,310
2023-02-22 2023-02-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 9,886 1,015,508 0.98
2023-02-14 2023-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -1,134 1,005,622 -0.11 51.21 -58,072 51,497,903
2023-02-10 2023-02-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 1,006,756 -1.18 54.45 -653,400 54,817,864
2023-02-10 2023-02-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18,500 1,018,756 1.85 2.67 49,395 2,720,079
2023-01-30 2023-01-27 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -832 1,000,256 -0.08 52.77 -43,905 52,783,509
2023-01-24 2023-01-20 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -2,326 1,001,088 -0.23 52.05 -121,068 52,106,630
2023-01-17 2023-01-12 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 19,634 1,003,414 2.00
2023-01-10 2023-01-09 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 983,780 -1.21 46.08 -552,960 45,332,582
2023-01-10 2023-01-09 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18,500 995,780 1.89 2.67 49,395 2,658,733
2022-12-30 2022-12-29 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 7,000 977,280 0.72 3.67 25,690 3,586,618
2022-12-12 2022-12-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 970,280 -1.22 47.50 -570,000 46,088,300
2022-12-12 2022-12-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18,500 982,280 1.92 2.67 49,395 2,622,688
2022-11-10 2022-11-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 963,780 -1.23 46.47 -557,640 44,786,857
2022-11-10 2022-11-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18,500 975,780 1.93 2.67 49,395 2,605,333
2022-10-11 2022-10-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 957,280 -1.24 57.50 -690,000 55,043,600
2022-10-11 2022-10-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18,500 969,280 1.95 2.67 49,395 2,587,978
2022-09-12 2022-09-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 950,780 -1.25 63.98 -767,760 60,830,904
2022-09-12 2022-09-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18,500 962,780 1.96 2.67 49,395 2,570,623
2022-08-09 2022-08-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 944,280 -1.25 62.50 -750,000 59,017,500
2022-08-09 2022-08-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 18,500 956,280 1.97 2.67 49,395 2,553,268
2022-07-12 2022-07-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 937,780 -1.26 47.95 -575,400 44,966,551
2022-07-12 2022-07-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 6,500 949,780 0.69 2.67 17,355 2,535,913
2022-07-12 2022-07-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 12,000 943,280 1.29 2.67 32,040 2,518,558
2022-06-22 2022-06-17 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 33,005 931,280 3.67 2.67 88,123 2,486,518
2022-06-09 2022-06-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 6,500 898,275 0.73 2.67 17,355 2,398,394
2022-06-09 2022-06-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -12,000 891,775 -1.33 44.09 -529,080 39,318,360
2022-06-09 2022-06-08 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 12,000 903,775 1.35 2.67 32,040 2,413,079
2022-05-02 2022-04-29 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -4,000 364,999 -1.08
2022-05-02 2022-04-29 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -4,000 891,775 -0.45 44.43 -177,720 39,621,563
2022-05-02 2022-04-29 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 4,000 895,775 0.45 2.67 10,680 2,391,719
2022-05-02 2022-04-21 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
J - Other -11,250 0 -100.00
2022-05-02 2022-04-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
J - Other -1,875 891,775 -0.21
2022-02-14 2022-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -1,057 893,650 -0.12 47.12 -49,806 42,108,788
2022-02-01 2022-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -931 894,707 -0.10 38.59 -35,927 34,526,743
2022-01-25 2022-01-21 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 36,951 36,951
2022-01-25 2022-01-21 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 26,051 895,638 3.00
2021-06-25 2021-06-24 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -6,250 368,999 -1.67
2021-06-25 2021-06-24 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -6,250 869,587 -0.71 65.61 -410,062 57,053,603
2021-06-25 2021-06-24 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 6,250 875,837 0.72 2.67 16,688 2,338,485
2021-05-25 2021-05-24 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -6,250 375,249 -1.64
2021-05-25 2021-05-24 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -6,250 869,587 -0.71 47.40 -296,250 41,218,424
2021-05-25 2021-05-24 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 6,250 875,837 0.72 2.67 16,688 2,338,485
2021-04-29 2021-04-28 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise -4,500 381,499 -1.17
2021-04-29 2021-04-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 4,500 869,587 0.52 2.67 12,015 2,321,797
2021-04-26 2021-04-23 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -6,250 385,999 -1.59
2021-04-26 2021-04-23 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -6,250 865,087 -0.72 46.13 -288,312 39,906,463
2021-04-26 2021-04-23 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise X 6,250 871,337 0.72 2.67 16,688 2,326,470
2021-03-11 2021-03-10 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise -6,250 392,249 -1.57
2021-03-11 2021-03-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -6,250 865,087 -0.72 50.74 -317,125 43,894,514
2021-03-11 2021-03-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 6,250 871,337 0.72 2.67 16,688 2,326,470
2021-02-11 2021-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
F - Taxes -688 865,087 -0.08 47.72 -32,831 41,281,952
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 11,250 11,250
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 45,000 45,000
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 1,875 865,775 0.22
2021-02-01 2021-01-28 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 7,500 863,900 0.88
2020-03-12 2020-03-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
G - Gift -161,656 847,025 -16.03
2020-02-14 2020-02-13 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -117,205 0 -100.00
2020-02-14 2020-02-13 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -55,398 1,008,681 -5.21 40.98 -2,270,155 41,334,739
2020-02-14 2020-02-13 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 117,205 1,064,079 12.38 2.14 250,819 2,277,129
2020-02-14 2020-02-12 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (Right to Buy)
M - Exercise X -117,206 117,205 -50.00
2020-02-14 2020-02-12 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale -52,075 946,874 -5.21 42.80 -2,228,966 40,529,048
2020-02-14 2020-02-12 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
M - Exercise 117,206 998,949 13.29 2.14 250,821 2,137,751
2020-02-12 2020-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Stock option (right to buy)
A - Award 56,250 56,250
2020-02-12 2020-02-10 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
A - Award 9,375 891,118 1.06
2019-09-26 2019-09-25 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -1,010 881,743 -0.11 25.64 -25,897 22,608,772
2019-09-26 2019-09-25 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -20,531 882,753 -2.27 25.24 -518,161 22,278,920
2019-09-25 2019-09-24 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -1,295 903,284 -0.14 24.96 -32,321 22,544,162
2019-09-25 2019-09-24 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -20,307 904,579 -2.20 24.56 -498,760 22,217,365
2019-09-25 2019-09-23 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -100 924,886 -0.01 25.53 -2,553 23,612,340
2019-09-25 2019-09-23 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
S - Sale X -20,758 924,986 -2.19 25.07 -520,362 23,187,549
2019-02-12 2019-02-08 4 APLS Apellis Pharmaceuticals, Inc.
Stock option (right to buy)
A - Award 95,000 95,000
2018-05-09 2018-05-07 4 APLS Apellis Pharmaceuticals, Inc.
Common Stock
J - Other 384,292 945,744 68.45
2018-02-21 2018-02-16 4 APLS Apellis Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 110,000 110,000
2017-11-08 3 APLS Apellis Pharmaceuticals, Inc.
Common Stock
1,122,904
2017-11-08 3 APLS Apellis Pharmaceuticals, Inc.
Common Stock
1,122,904
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)